« Back
Home /
AZD8330

AZD8330

Item no.	HY-12058-5mg
Manufacturer	MedChem Express
CASRN	869357-68-6
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.14
Citations	[1]Cohen RB, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9.\|[2]Baranski Z, et al. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Genes Cancer. 2015 Nov;6(11-12):503-12.
Smiles	IC1=CC(F)=C(C=C1)NC(N2C)=C(C=C(C2=O)C)C(NOCCO)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ARRY-424704,ARRY-704
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	MEK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	461.23
Product Description	AZD8330 (ARRY-424704) is a potent, uncompetitive MEK1/MEK2 inhibitor, with an IC50 of 7 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 100 mg/mL
Manufacturer - Pathway	MAPK/ERK Pathway
Isoform	MEK1; MEK2
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12058-5mg-safety-datasheet.pdf